NA
RYTM icon

NewEdge Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

NewEdge Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5
Closed -$230 – 3942
2023
Q4 		$230 Hold
5
– – ﹤0.01% 3596
2023
Q3 		$115 Buy
+5
New +$112 ﹤0.01% 3362

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

NewEdge Advisors's RYTM Position: Q1 2024 in Review

NewEdge Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2024, closing a stake of 5 shares — an estimated $230 sold.

NewEdge Advisors first reported a position in RYTM in Q3 2023 and held it in 2 quarters. The position peaked at $230 in Q4 2023. 167 funds tracked by Wall St. Rank hold RYTM as of Q1 2024.

  • NewEdge Advisors reported no remaining Rhythm Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • NewEdge Advisors sold 5 Rhythm Pharmaceuticals shares in Q1 2024, an estimated $230.
  • NewEdge Advisors first reported a position in Rhythm Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • NewEdge Advisors's Rhythm Pharmaceuticals position peaked at $230 in Q4 2023.
  • 167 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2024.

Based on NewEdge Advisors's 13F filing for Q1 2024, filed 14 May 2024.